Abstract:Diffuse midline gliomas (DMGs) are aggressive childhood brain tumors with the H3K27M mutation in the H3F3A or H3C2 gene. Despite treatment advances, radiotherapy is the only viable option, but 99% of patients die within 1.5-2 years. Therefore, there is an urgent need to identify potential novel therapeutic targets for the treatment of DMGs. Ubiquitin-specific protease 1 (USP1) is a key deubiquitinating enzyme involved in genome integrity, cell cycle regulation, and cell homeostasis. USP1 is overexpressed in various cancers, including gliomas, is linked to poor prognosis. It promotes glioma stem cell (GSC) self-renewal and radio-resistance by regulating ID1 and CHEK1. Our recent findings show that ID1 is crucial for DMG invasion and migration. Inhibiting USP1 suppresses malignant growth, enhances radiation sensitivity, and improves chemotherapy response, highlighting its potential for combined therapies. However, USP1's role in DMGs and its feasibility as a therapeutic target remain poorly understood. In this study, we investigated USP1 in DMGs for the first time. RNA sequencing revealed high USP1 expression in DMG patient samples and cell lines, directly linked to the H3K27M mutation. Correcting this mutation reduced USP1 expression in DMG cell lines. Pharmacologic inhibition of USP1 with the specific inhibitor SJB3-019A significantly reduced DMG cell proliferation, triggered apoptosis, and altered cell cycle profile. SJB3-019A-mediated USP1 inhibition decreases migration and invasion in multiple patient-derived DMG cell lines. Additional in vitro experiments revealed that USP1 inhibition leads to a significant decrease in the expression of ID1 and pAKT, suggesting the ID1/AKT pathway as a potential mechanism underlying the observed effects. H3K27M-mediated activation of USP1 in DMG is a promising therapeutic target, with inhibition by SJB3-019A reducing tumor aggressiveness by inhibiting invasion and migration. We will next assess SJB3-019A's efficacy in vivo using genetically engineered isogenic mouse models (GEMM) with DNp53/PDGFRA/H3.3K27M (PPK) alterations and evaluate USP1 inhibition combined with radiation therapy as a potential radiosensitizer in DMGs.

USP7 Inhibition Induces Apoptosis in Glioblastoma by Stabilizing ARF4

USP7 inhibition induces apoptosis in glioblastoma by enhancing ubiquitination of ARF4

Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth

USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression

Ubiquitin-specific protease 4 promotes glioblastoma multiforme via activating ERK pathway

USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1

Suppression of the USP10/CCND1 Axis Induces Glioblastoma Cell Apoptosis

USP9X deubiquitinates TRRAP to promote glioblastoma cell proliferation and migration and M2 macrophage polarization

Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)

Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing

Stabilization of KPNB1 by deubiquitinase USP7 promotes glioblastoma progression through the YBX1-NLGN3 axis

Ubiquitin-specific Protease 2a Stabilizes MDM4 and Facilitates the P53-Mediated Intrinsic Apoptotic Pathway in Glioblastoma.

Identification of Ubiquitin-Specific Protease 32 As an Oncogene in Glioblastoma and the Underlying Mechanisms

Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1

Loss of Deubiquitylase USP2 Triggers Development of Glioblastoma Via TGF-β Signaling.

Exploring Ubiquitin-specific proteases as therapeutic targets in Glioblastoma

Deubiquitinase USP9X Deubiquitinates Β-Catenin and Promotes High Grade Glioma Cell Growth

Overexpression of Ubiquitin Specific Proteases 44 Promotes the Malignancy of Glioma by Stabilizing Tumor-Promoter Securin.

Targeting PUS7 Suppresses Trna Pseudouridylation and Glioblastoma Tumorigenesis

Cnsc-49. Elucidating Therapeutic Potential Of Usp1 Inhibition In Diffuse Midline Gliomas

USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth